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MCF-7member of Bcl-2 family, contains a BH2 domain and a putative BH3 domain. It
was found to be highly expressed in normal breast tissues, and was associated with favorable prognosis in
breast cancer patients. Here, we reported that the mRNA levels of BCL2L12 and its transcript variant
BCL2L12A could be upregulated upon cisplatin treatment in MDA-MB-231 breast cancer cells. Knockdown of
BCL2L12 and BCL2L12A dramatically inhibited cisplatin-induced apoptosis. In contrast, ectopic expressions of
each of the proteins promoted cisplatin-induced apoptosis. These results indicated that decreased
expressions or loss of BCL2L12 and BCL2L12A may contribute to the cisplatin resistance in breast cancer
patients. Furthermore, we found that cisplatin-induced downregulation of β-catenin was partially
suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231 cells, which indicated that knockdown
of these two proteins may stabilize β-catenin in cisplatin-induced apoptosis. In short, we proposed that
BCL2L12 and BCL2L12A may play an important role in cisplatin-induced apoptosis in MDA-MB-231 breast
cancer cells.
Crown Copyright © 2008 Published by Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the most ubiquitous malignancy among women,
and therefore an important public health issue [1]. It is expected to
account for 26% (182,460) and rank the ﬁrst of all new cancer cases
among American women, and accounts for 15% of all female cancer
deaths [2]. Among the wide variety of drugs used in breast cancer
chemotherapy regimens is doxorubicin that possesses a broad
spectrum of anti-tumor activity, cisplatin, and carboplatin [3–5].
Cisplatin (cis-diamminedichloroplatinumII, CDDP) is one of the
most potent anti-tumor agents known, displaying clinical activity
against a wide variety of solid tumors, including breast cancer. Its
cytotoxic mode of action is mediated by the interaction with DNA to
form DNA adducts, primarily intra-strand crosslink adducts, which
activate several signal transduction pathways, including those invol-
ving ATR, p53, p73 and MAPK, and culminate in the activation of
apoptosis [6–10].
Although cisplatin is effective against many human tumors, some
are intrinsically resistant. And even among initially sensitive tumors,
acquired resistance develops commonly during treatment. The rapid
development of techniques for molecularly engineering cells to
disrupt the expression of single genes has provided an alternative86 21 64437403.
08 Published by Elsevier B.V. All rigstrategy that yielded novel insights into previously unsuspected
mechanisms that control cisplatin sensitivity. C-Jun transcription
factor AP1 in mouse and Lyn tyrosine kinase in chicken are among
those genes whose knockout may lead to cisplatin resistance [11].
Several other genes were also found to be associated with cisplatin
sensitivity. AKT was reported to promote cisplatin resistance in
human ovarian cancer cells, while c-myc sensitizes colon cancer cells
SW480 and SW620 to cisplatin-induced apoptosis [12,13]. And as a
well established anti-tumor protein, p53 plays a central role in
chemotherapy-induced apoptosis; however, its importance as a
determinant of cisplatin sensitivity differs in various cell lines and
tissues [11]. In all, cisplatin resistance is cell type and tissue dependent
and the clinical mechanisms that lead to cisplatin resistance are
complex, which means a large amount of work remains to be done.
Upstream factors involved in the cellular response to DNA damage
mediate the induction of a network that transmits both pro- and anti-
apoptotic signals. Any interference that favors anti-apoptotic signal
transduction or abrogates pro-apoptotic pathways, including the
transcriptional and translational responses, is a potential mechanism
of cisplatin resistance [14]. Apoptotic events are regulated by a
number of proteins that exert either positive (pro-apoptotic) or
negative (anti-apoptotic) effects on programmed cell death. Proteins
participating in these events include members of the Bcl-2 family
which are characterized by the presence of at least one of the BH1,
BH2, BH3 and BH4 domains. The BH1 and BH2 domains are present in
all anti-apoptotic proteins, while the BH3 domain is present in thehts reserved.
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Bcl-2 and Bcl-XL [15–17]. Most apoptosis-related genes regulate
cellular fate as a response to anticancer drugs, and the levels of various
Bcl-2 family proteins have been shown to determine the responses of
tumor cells to chemotherapies [18,19].
BCL2L12 is a newly identiﬁed member of Bcl2 family. BCL2L12 has
two splicing variants: the classical form of the gene and a truncated
form called BCL2L12A which lacks exon 3 (143 bp) [20]. BCL2L12 was
predicted to contain a highly conserved BH2 domain and a BH3-like
motif which contributed to its pro-apoptotic activity in UV treated
cells [20,21]. BCL2L12A, although lacked the BH2 domain, shared
exactly the same sequence with BCL2L12 from the ﬁst amino acid to
the 120th amino acid. BCL2L12 and BCL2L12A were highly expressed
in normal breast tissues [20]. Statistic analysis revealed that BCL2L12-
positive breast tumors were mainly of lower stage (I/II) or grade (I/II)
and that breast cancer patients with positive BCL2L12 expressionwere
almost 5 times less likely to relapse or die, which conﬁrmed an
association of BCL2L12 with favorable prognosis [22]. But the under-
lying mechanisms remain to be studied.
In the present study, we intended to clarify the favorable role of
BCL2L12 in breast cancer patients, and uncover the underlying
molecular mechanism to this clinical phenomenon. To this end, we
explored an shRNA strategy to knockdown endogenous BCL2L12. And
we found that knockdown of BCL2L12 and BCL2L12A expressions with
a gene speciﬁc shRNA dramatically suppressed cisplatin-induced
apoptosis in MDA-MB-231 cells, while ectopic expressions of BCL2L12
or BCL2L12A promoted cisplatin-induced apoptosis. In a conclusion,
our results identiﬁed that BCL2L12 and BCL2L12A promoted cisplatin-
induced apoptosis in MDA-MB-231 breast cancer cells and suggested
that knockdown of these two proteins may stabilize β-catenin in
cisplatin-induced apoptosis.
2. Materials and methods
2.1. Chemicals and reagents
Fetal calf serum, Trizol Reagent and Lipofectamine reagent were
purchased from Invitrogen. DMEM medium and cisplatin were from
Sigma Chemical. Cisplatin was dissolved in PBS at a concentration of
10 mM and diluted to indicated concentrations when inducing
apoptosis. Anti-Bad, anti-Bid, anti-Bax, anti-Bak, anti-Bcl-2 and anti-
PARP antibodies were purchased from Cell Signaling Technology.
Anti-EGFP antibody was purchased from Roche Applied Science.
Anti-GAPDH antibody was purchased from KangChen Bio-tech.
Chemiluminescence (ECL) assay kit was purchased from Tiangen
Biotech Company.
2.2. Plasmid construction
The ﬁrst exon of human BCL2L12 was isolated from genome
DNA of human lung cell line PG-BE1 by PCR with primers (5′-
ATACTCGAGATGGGACGGCCCGCTGGGCTG-3′ and 5′-GCCATGGAGG-
CACCTGGTCCGGGGCCCCAC-3′). The rest of BCL2L12's open reading
frame was ampliﬁed from brain cDNA library with primers (5′-
GGGGCCCCGGACCAGGTGCCTCCATGGC-3′ and 5′-ATAGAATTCCG-
TCCAATGGCAAGTTCAAG-3′). Then the entire cDNA of BCL2L12 was
ampliﬁed using primers (5′-AAAGAATTCATGGGACGGCCCGCT GG-3′ and
5′-GTGCTCGAGTCAGTCCAATGGCAAGTTC-3′) and cloned into pcDNA3.0-
GFP [23]. For knockdown of BCL2L12 and BCL2L12A expressions, two
complementary oligonucleotides targeted to the BCL2L12 gene were
designed: 5′-GATCCGGAAGCCATACTGCGGAGGTTCAAGAGACCTCCG-
CAGTATGGCTTCCTTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAAAGGAA-
GCCATACTGCGGAGGTCTCTTGAACCTCCGCAGTATGGCTTCCG-3′. Plasmid
pSi-BCL2L12 was constructed by inserting the annealed complementary
oligonucleotides into the pSilencer2.1-U6-neo vector (Ambion). All
constructs were conﬁrmed by DNA sequencing.2.3. Cell culture, transfection and western blot
MDA-MB-231 breast cancer cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) and supplemented with 10% fetal
bovine serum.MCF-7breast cancer cellswere cultured in10%FBS–DMEM
and supplemented with 0.01 mg/ml bovine insulin. Cell transfectionwas
performed with Lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions. For stable transfection, 48 h after transfec-
tion, the cells were selected in the DMEM containing G418 (400 μg/ml).
After 2–3 weeks' growth in G418-containing medium the individual
G418-resistant clones were selected, expanded and validated.
2.4. Western blot analysis
Western blot experiments were used to measure certain proteins.
Brieﬂy, the cells were lysed in 1× SDS lysis buffer (40 mM Tris pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% SDS, 1 mM aprotinin, 1 mM PMSF and
10 μg/ml Leupeptin). A total of 50 μg of protein from each sample was
electrophoresed by 8% or 10% SDS-PAGE and then transferred to a
PVDF membrane. After blocking with PBS containing 5% nonfat milk
and 0.1% Tween 20 overnight, the membrane was incubated with
primary antibody at room temperature for 2 h. After washingwith PBS
containing 0.1% Tween 20 three times, each for 10 min, the membrane
was then incubated with horseradish peroxidase labeled secondary
antibody for another 1 h at room temperature. The membrane was
then developed using the enhanced chemiluminescent (ECL) detec-
tion system.
2.5. Analysis of apoptosis
2.5.1. Analysis of nuclear morphology by ﬂuorescence staining
Cells grown on the glass coverslips were ﬁxed with 4% para-
formaldehyde/PBS for 30min, washed for 15min in 0.1% Triton X-100/
PBS, and incubated in dark with Hoechst 33258 (20 μg/ml) for 15 min.
After the coverslips werewashed in PBS, positive nuclei were counted.
Normal nuclei and apoptotic nuclei (condensed new moon-type or
fragmented chromatin) were easily distinguished. A minimum of 300
cells from three different microscopic ﬁelds were counted to obtain
reliable estimates of cell apoptosis in three independent experiments.
2.5.2. Apoptosis of GFP-positive cells was assessed by PI staining
24 h after transfection, the cells were treated with indicated
amounts of cisplatin for 2 h and incubated in fresh media for another
24 h. Then, the adherent and non-adherent cells were collected,
washed twice in phosphate-buffered saline (PBS), ﬁxed with 4% PFA,
and permeated in 0.1% Triton X-100/PBS on ice for 10 min. The ﬁxed
cells were washed and stained with propidium iodide mixture
containing 50 μg/ml propidium iodide, 0.05% Triton X-100, 37 μg/ml
EDTA, and 100 U/ml ribonuclease in PBS. After incubation for 45 min
at 37 °C, the DNA content was determined by quantitative ﬂow
cytometry with standard optics of FACScan ﬂow cytometer (Becton-
Dickinson FACStar), and GFP-positive cells were gated and the
percentage of apoptosis was quantitated from sub-G1 events.
2.5.3. Apoptosis analysis by annexin-V and PI staining
This analysis was performed as described before [24]. Brieﬂy,
adherent and non-adherent cells were collected, washed twice in
phosphate-buffered saline (PBS), and then resuspended in binding
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2).
195 μl of cell suspension containing 105 cells was taken, and 5 μl of
annexin-V–FITCwas added,mixed, and incubated for 10min in thedark.
After that, the cells werewashed twice in PBS and resuspended in 190 μl
of binding buffer. 10 μl of 20 μg/ml PI was added and then analyzed by
ﬂuorescence-activated cell sorting. Cells in the early stage of apoptosis
could be stainedwith annexin-Vbut not PI. Thenecrotic and late stage of
apoptotic cells were stained by both annexin-V–FITC and PI.
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Total mRNA samples of MDA-MB-231 breast cancer cells were
extracted using Trizol reagent (Invitrogen) according to the manufac-
turer's instructions. Samples (1.0 μg) were used as templates to
perform the RT-PCR assay. The RT-PCR and real-time PCR was
performed by using TaKaRa RNA PCR Kit (AMV) Ver. 3.0 and SYBR
Premix Ex Taq II according to the manual (TaKaRa), respectively. The
cDNAwas subjected to denaturation at 95 °C for 5 min, followed by 30
cycles (94 °C for 30 s, 57 °C for 30 s, and 72 °C for 45 s) and incubated atFig. 1. BCL2L12 and BCL2L12A mRNAwere upregulated upon cisplatin treatment in MDA-MB
drug (0, 1, 2.5, 5, 10, 25, 50, and 100 μM) for increasing periods of time (24, 48, and 72 h), and
indicated amount of cisplatin for 2 h and then incubated in freshmedia for 24 h. (C) MDA-MB-
mRNA level was further quantiﬁed by real-time PCR analysis. (E and G) The BCL2L12A mR
electrophoresis results. Total cellular RNAwas isolated using trizol reagent, and 1 μg RNAwas
actin was used as an internal control. The data were presented as increases (n-fold) compar
experiments. While BCL2L12A levels were relatively low in themiddle panel of Fig. 1B and C, w
distinguishable vision of BCL2L12A in the lower panels.72 °C for 10min and 4 °C for 5min. Then products were applied to 1.5%
agarose gel electrophoresis. Primers used for conventional PCR were
as follows: BCL2L12-F 5′-TTCCGCCCTTTCTACGCTGG-3′ and BCL2L12-R
5′-GCCTCCGCAGTATGGCTTCC-3′; β-actin-F 5′-ATGGATGATGATAT-
CGCCGC-3′ and β-actin-R 5′-CATCACGATGCCAGTGGTAC-3′. And the
densitometric programme used was Totallab 2.01. Primers used for
real-time PCR were as follows: L12-real-time-F 5′-AAGCCCTGCCCAA-
GAAGAGCCA-3′, L12-real-time-R 5′-CCAGGCTCTAAACCATAGCAGGG-
3′; Real-time RT-PCR was performed using an iCycler iQ multicolor
real-time PCR detection system (Bio-Rad) with the following cycling-231 breast cancer cell. (A) MDA-MB-231 cells were exposed to increasing doses of the
cell viability was measured by the MTT assay. (B) MDA-MB-231 cells were treated with
231 cells were treated with 10 μg/ml cisplatin for indicated times. (D and F) The BCL2L12
NA level was quantiﬁed by a densitometric programme named Totallab based on the
used to perform RT-PCR analysis to assess the mRNA levels of BCL2L12 and BCL2L12A. β-
ed to the PBS-treated samples. Each bar represents the mean±SD of three independent
e increased the PCR cycles from 30 to 35, and used a higher intensity of UV light to get a
Fig. 2. shRNA-mediated knockdown of BCL2L12 and BCL2L12A in MDA-MB-231 breast
cancer cells. (A) shRNA-mediated knockdown of BCL2L12. MDA-MB-231 cells were
transfected with pSilencer 2.1 or pSi-BCL2L12 respectively. The stable cell lines were
chosen as mentioned earlier. The total RNA of each clone was extracted and subjected to
RT-PCR analysis of BCL2L12 and BCL2L12A mRNA levels. (B) Quantiﬁcation of BCL2L12
mRNA level with real-time PCR. (C) Quantiﬁcation of BCL2L12A mRNA level using
Totallab 2.01. (D) Inhibition of BCL2L12 protein expression. GFP-BCL2L12 was co-
transfected with GFP and pSilencer2.1 (a) or pSi-BCL2L12 (b) into MDA-MB-231 cells.
Cell lysates were subjected to immunoblot analysis with antibody to GFP. GFP was used
as a negative control and GAPDH as a loading control. (E, F) ThemRNA levels and protein
levels of other Bcl-2 family members in cells stably transfected with pSilencer2.1 or pSi-
BCL2L12 were analyzed.
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15 s at 94 °C, 20 s at 56 °C, and 15 s at 72 °C. β-actin was employed as
an internal reference under the same experimental conditions. Data
were analyzed by using iCycler iQ software (Bio-Rad). The values were
obtained through normalizing BCL2L12 copies to β-actin copies.
2.7. Cell viability assay
Relative cell viability was determined by MTT assay. Cells (1×104
cells/well) were plated in 96-well microtiter plates. Twenty four hours
after transfection, cells were incubated with different concentrations
of cisplatin for another 24 h at 37 °C. MTT was added to the culture
medium to yield a ﬁnal MTT concentration of 0.5 mg/ml following cell
treatment and the incubation was continued for 4 h at 37 °C. The
pellets were dissolved with dimethyl sulfoxide at room temperature
for 10min. Cell viability was determined bymeasuring the absorbance
of the converted dye at a wavelength of 490 nm.
3. Results
3.1. BCL2L12 mRNA and BCL2L12A mRNA were upregulated upon
cisplatin treatment in MDA-MB-231 breast cancer cells
As BCL2L12 and BCL2L12Awere highly expressed in normal breast
tissues and associated with a favorable prognosis in breast cancer
patients [20,22], we investigated their functions in breast cancer cells
and their contributions to cisplatin-based chemotherapy. To deter-
mine the sensitivity of MDA-MB-231 cells to cisplatin, the cells were
exposed to increasing doses of the drug (0, 1, 2.5, 5, 10, 25, 50, 100 μM)
for increasing periods of time (24, 48, and 72 h), and cell viability was
measured by the MTT assay (Fig. 1A). We then examined the
expressions of BCL2L12 and BCL2L12A in MDA-MB-231 breast cancer
cells treated with cisplatin (CDDP). RT-PCR was performed to analyze
the mRNA levels of both proteins in vehicle (PBS)- or CDDP-treated
MDA-MB-231 cells. As depicted in Fig. 1B, the mRNA levels of both
proteins were signiﬁcantly increased upon CDDP treatment in a dose-
dependent manner. In order to detect themRNA levels of BCL2L12 and
BCL2L12A treated with cisplatin in different times, the cells were ﬁrst
treated with 20 μM cisplatin for 2 h and then incubated in fresh media
for the indicated times. As the results shown in Fig. 1C, both the mRNA
levels of BCL2L12 and BCL2L12A were upregulated in a time-
dependent manner before 24 h and downregulated afterwards (Fig.
1C). The BCL2L12 mRNA level was further quantiﬁed by real-time PCR
analysis (Fig.1D and F), which gave a similar result as the conventional
PCR method. The BCL2L12A mRNA level was quantiﬁed by a
densitometric programme named Totallab based on the electrophor-
esis results (Fig. 1E and G). BCL2L12A is a splicing variant of BCL2L12,
and BCL2L12 shares all the sequences BCL2L12A has (Fig. 1H). The
primers designed for the detection of BCL2L12 in real-time PCR can
only recognize BCL2L12 but not BCL2L12A. However, it may not be
possible for us to design such pair of primers for BCL2L12A in real-
time PCR. So we can only quantify the levels of BCL2L12A with the
conventional PCR.
3.2. shRNA-mediated knockdowns of BCL2L12 and BCL2L12A in MDA-
MB-231 breast cancer cells
The fact that BCL2L12 and BCL2L12A mRNA were upregulated
dramatically upon cisplatin treatment in MDA-MB-231 cells drove us
to investigate whether the elevated expressions of both proteins were
associated with CDDP-induced apoptosis. To do so, we employed an
shRNA approach to knockdown the endogenous BCL2L12 and
BCL2L12A. Two complementary oligonucleotides targeted to the
BCL2L12 gene were designed, denatured and inserted into pSilen-
cer2.1-U6-neo plasmid. Then, pSilencer2.1-U6-BCL2L12 (pSi-BCL2L12)
and mock vector were transfected into MDA-MB-231 cells respec-tively, and the cells stably expressing pSi-BCL2L12 and mock vector
were selected using G418 (400 μg/ml). The total cellular RNAs of stably
transfected clones were subjected to analyze the mRNA levels of both
proteins. As shown in Fig. 2A, B and C, the expressions of these two
proteins were downregulated in pSi-BCL2L12-expressing cells. In
order to test the speciﬁcity of pSi-BCL2L12, we also analyzed the
expressions of other Bcl-2 family members, such as Bcl-2, Bcl-xl, Bax,
Bim and Bad (Fig. 2E and F), which remained unchanged in MDA-MB-
231/pSi-BCL2L12 cells. To visualize the reduction of BCL2L12 expres-
sion in the protein level, we further transfected cells with a GFP-
BCL2L12 fusion gene. The expression of GFP-BCL2L12 was reduced by
approximately 80% in cells transfected with pSi-BCL2L12 compared to
that in control cells (Fig. 2D). The expression of GFP was used as a
negative control. These results demonstrated that the expressions of
BCL2L12 and BCL2L12A in MDA-MB-231 breast cancer cells were
suppressed by pSi-BCL2L12 with high efﬁciency and speciﬁcity.
3.3. Knockdown of BCL2L12 and BCL2L12A resulted in elevated resistance
of MDA-MB-231 to CDDP-induced apoptosis
Having established that BCL2L12 and BCL2L12A expressions were
reduced signiﬁcantly by pSi-BCL2L12, we analyzed whether the
downregulation of these two proteins would affect the sensitivity of
MDA-MB-231 cells to CDDP-induced apoptosis. To do so, MDA-MB-
Fig. 3. Knockdown of BCL2L12 and BCL2L12A resulted in elevated resistance of MDA-MB-231 to CDDP-induced apoptosis. (A) Cells stably transfectedwithmock vector or pSi-BCL2L12
were treated with 20 μMor 50 μMCDDP for 2 h, and then incubated in freshmedia for another 24 h. After treatment, the adherent cells were stainedwith Hoechst 33258. At least 300
cells were counted from three different microscopic ﬁelds and each value was mean±SD of three independent experiments. (B) Cells were harvested, stained with propidium iodide,
and then subjected to ﬂow cytometry analysis (n=3; pb0.05). (C) Cells were treated with PBS or 20 μM cisplatin for 2 h, and then incubated in fresh media for another 24 h. Adherent
and non-adherent cells were harvest, washed with PBS and stained with Annexin-V and PI as described above. (D)Western blot analysis of PARP cleavage in total cell lysates of MDA-
MB-231 cells stably transfected with mock vector or pSi-BCL2L12 and treated with vehicle (PBS) or cisplatin of indicated concentrations for 24 h. (E) Effect of pSi-BCL2L12 on β-
catenin protein level. MDA-MB-231/pSilencer (1) and MDA-MB-231/pSi-BCL2L12 (2) cells were treated with vehicle (PBS) or cisplatin as in C. And then, cells were subjected to
western blot analysis with antibodies to β-catenin and β-tubulin.
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(IC15) or 50 μM (IC30) CDDP respectively for 2 h and then incubated in
fresh media for another 24 h. As measured by Hoechst staining assay
(Fig. 3A), the apoptosis rates were decreased by about 40% and 60%
respectively. The propidium iodide-based FACS assay also gave the
similar result (Fig. 3B). The percentage of apoptotic cells was a little
higher measured by PI staining compared with Hoechst staining. The
reason for this may be that the cells subjected to PI-based FACS assay
included both adherent and non-adherent cells, while only adherent
cells were analyzed in the Hoechst staining assay. To get a better
analysis of apoptosis, Annexin-V/PI double staining method was used.
As shown in Fig. 3C, the percentage of cells in the early stage of
apoptosis (Annexin-V+/PI−) and the percentage of cells in the late
stage of apoptosis plus necrotic cells (Annexin-V+/PI+) were evidently
higher in MDA-MB-231/pSilencer cells than in MDA-MB-231/pSi-
BCL2L12 cells. Because PARP cleavage is a hallmark of apoptosis [25],
in order to conﬁrm the apoptosis suppression effect of pSi-BCL2L12 on
MDA-MB-231 cells, we further analyzed the effect of pSi-BCL2L12 on
PARP cleavage in CDDP-treated cells. As shown in Fig. 3D, the cleavage
of PARP was obviously suppressed in cells stably transfected with pSi-
BCL2L12. These results indicated that knockdown of BCL2L12 and
BCL2L12A with pSi-BCL2L12 elevated the resistance of MDA-MB-231
cells to CDDP-induced apoptosis. In order to further investigate the
signaling pathway BCL2L12 and BCL2L12A participated in cisplatin-
induced apoptosis, we analyzed several apoptosis and tumor-
associated proteins, such as Bcl-2 and β-catenin. Of those beingexamined, β-catenin was found to be differently expressed in MDA-
MB-231/pSilencer and MDA-MB-231/pSi-BCL2L12 cells when treated
with cisplatin. As shown in Fig. 3E, β-catenin was downregulated
upon cisplatin treatment in MDA-MB-231/pSilence cells, which was
suppressed in MDA-MB-231/pSi-BCL2L12 cells. This result indicated
that knockdown of BCL2L12 and BCL2L12A suppressed cisplatin-
induced downregulation of β-catenin. These suggested that knock-
down of these two proteins might stabilize β-catenin in cisplatin-
induced apoptosis. But the underlying mechanisms still remained to
be studied.
3.4. Knockdown of BCL2L12 and BCL2L12A did not affect the cell cycle
and cell proliferation rate of MDA-MB-231 cells
Clinical observation showed that BCL2L12 and BCL2L12A expres-
sions were associated with and could be used as amolecularmarker of
favorable prognosis for breast cancer [22,26]. We considered the
possibility that knockdown of BCL2L12 and BCL2L12Amight affect the
cellular proliferation rate of breast cancer cells. We therefore
compared the growth kinetics of MDA-MB-231/pSilencer cells and
MDA-MB-231/pSi-BCL2L12 cells. However, Fig. 4A showed that both
cell lines gave the similar growth rates, which indicated that BCL2L12
and BCL2L12A expressions did not affect the growth of MDA-MB-231
cells. To gain further insight into whether the expressions of BCL2L12
and BCL2L12A had a subtle effect on cell growth, we made use of ﬂow
cytometry to compare the cell cycles of these two cell lines. The data
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BCL2L12 cells in G1, S, and G2/M phase were not statistically distinct
from that of MDA-MB-231/pSilencer cells. Taken together, we
concluded that the favorable functions of BCL2L12 and BCL2L12A in
MDA-MB-231 breast cancer cells might not be due to growth
suppression, but by inﬂuencing the tumor's sensitivity to anti-tumor
drugs.
3.5. Ectopic expressions of BCL2L12 and BCL2L12A promoted CDDP-
induced apoptosis in MDA-MB-231 cells
BCL2L12 and BCL2L12A share the same sequence from the ﬁrst
amino acid to the 120th amino acid, but have totally different amino
acid sequences from the 121st amino acid to the last ones because of
the reading frame shift (Fig. 5A). BCL2L12-shRNA recognized and
targeted to the C-terminal of BCL2L12 mRNA and 3′-untranslational
region of BCL2L12A mRNA respectively. As shown in Fig. 2, bothFig. 4. Knockdown of BCL2L12 and BCL2L12A did not affect the cell cycle and cell
proliferation rate of MDA-MB-231 cells. (A) Cellular proliferation analysis. 3×103 cells of
MDA-MB-231/pSi (circle) or MDA-MB-231/pSi-BCL2L12 (triangle) were seeded and
relative cell number was measured using MTT kit at the indicated times. (B) Cell cycle
analysis. The distribution of each phases of asynchronous cells including MDA-MB-231/
pSi and MDA-MB-231/pSi-BCL2L12 cells was quantitated by ﬂow cytometry. The
percentages of G0/G1, S, and G2/M were listed. (C) Statistical analysis of cell cycle
distributions of MDA-MB-231/pSi andMDA-MB-231/pSi-BCL2L12 cells. The data shown
are means±SD of three independent experiments.proteins were knocked down by pSi-BCL2L12. In order to clarify the
individual effects of BCL2L12 and BCL2L12A in cisplatin-induced
apoptosis, the cDNA of both genes were cloned and inserted into
pcDNA3.0-GFP. Then, EGFP tagged BCL2L12 and BCL2L12A were
transfected into MDA-MB-231 cells respectively (Fig. 5B, C). To testify
the apoptosis-associated functions of these two proteins, 36 h after
transfection, cells were treated with 20 μM cisplatin for 2 h, and then
incubated in fresh media for another 24 h. Afterwards, the cells were
harvested and stained with Hoechst 33258 (Fig. 5C). The statistic
results showed that ectopic expressions of GFP-BCL2L12 and GFP-
BCL2L12A promoted CDDP-induced apoptosis (Fig. 5D). In order to
get a better result, the adherent and non-adherent cells were
harvested, ﬁxed with 4% PFA, Permeabilized with 0.1% Triton X-100,
stained with PI, and then subjected to FACS analysis. GFP-positive
cells were gated and the percentage of apoptosis was quantitated
from sub-G1 events. Moreover, ectopic expressions of BCL2L12 and
BCL2L12A markedly increased the cleavage of PARP (Fig. 5F). These
results showed that both proteins could promote CDDP-induced
apoptosis.
4. Discussion
Bcl-2 family proteins serve as critical regulators of pathways
involved in apoptosis, acting to either inhibit or promote cell death
[27]. Sequence comparison of Bcl-2 family members has revealed four
recurring motifs, commonly denoted Bcl-2 Homology domains (BH1
to BH4), which are indispensable in their apoptosis-associated
functions [28–30]. BCL2L12 is a newly identiﬁed member of Bcl-2
family. Although it was predicted to contain a highly conserved BH2
domain and a BH3 like motif, its function in apoptosis remained
elusive [20,21]. It was reported that BCL2L12 could interact with Bcl-
xL and promoted UV-induced apoptosis, while Stegh, A.H. and
colleagues found that BCL2L12 inhibited post-mitochondrial apoptosis
signaling in glioblastoma through interacting with and neutralizing
caspase-7 [21,31]. However, it is not rare for a cellular protein to exert
both anti-apoptotic and pro-apoptotic functions, such as Hsp70,
which protects cells from heat shock, nitric oxide exposure and many
other environmental stresses, while promoting TNF-α mediated
apoptosis by binding IKK-γ and impairing NF-κB survival signaling
[32–34]. And even Bcl-2 itself, one of the most potent anti-apoptotic
proteins, could promote apoptosis in some situations [35,36]. These
ﬁndings suggested that BCL2L12 could have different functions upon
exposure to different cytotoxic stimuli.
BCL2L12 can also function distinctly in different cell types. For
example, overexpression of BCL2L12 in mammary tumors was
correlated with improved disease-free and overall survival, while
BCL2L12 expression, in particular, expression of a shorter isoform
BCL2L12A, was associated with tumor progression and poor prognosis
in colon cancer [22,26,37]. These ﬁndings suggested that the functions
of BCL2L12 and BCL2L12A might be dependent on the cell context and
may help to explainwhy BCL2L12 acted as an anti-apoptotic protein in
glioblastoma [31], while exerted pro-apoptotic function in MDA-MB-
231 breast cancer cells in our work.
Alterations of BCL2L12 mRNA level were also found in HL-60 and
MCF-7 cells upon several other anti-tumor drugs treatment. Etoposide
and topotecan downregulated BCL2L12 mRNA in HL-60 cells, and
cisplatin and toxal downregulated BCL2L12 mRNA in MCF-7. And the
mRNA level of BCL2L12 stayed stable in HL-60 and MCF-7 when
methotrexate and etoposide were used respectively. Furthermore, the
mRNA level of BCL2L12 was ﬁrst upregulated and then downregulated
in HL-60 cells when the cells were treated with cisplatin, carboplatin
or doxorubicin [38–43]. Because the aim of our research was to study
the BCL2L12 associated molecular mechanism of cisplatin-based
chemotherapy on breast cancer, we ﬁrst detect the expression of
BCL2L12 in MDA-MB-231 cells in cisplatin-induced apoptosis. And we
found that both the BCL2L12 and BCL2L12A mRNA levels were
Fig. 5. Ectopic expressions of BCL2L12 and BCL2L12A promoted CDDP-induced apoptosis. (A) Schematic representations of BCL2L12 and BCL2L12A. (B) Western blot analysis of GFP,
GFP-BCL2L12 and GFP-BCL2L12A expression in MDA-MB-231 cells. (C) Apoptosis was assayed morphologically. Cells transiently transfected with GFP, GFP-BCL2L12 and GFP-
BCL2L12Awere treated with 20 μM cisplatin for 2 h and incubated in fresh media for another 24 h. The fragrantation and condensation of apoptosis cells' nucleus were visualized by
Hoechst 33258 staining. The apoptotic cells were indicated with white arrows. (D) Quantiﬁcation of apoptosis rates. The apoptosis rates were counted amount GFP-positive cells, and
at least 300 cells were counted from three different microscopic ﬁelds and each value was the mean±SD of three independent experiments. (E) Cells were treated as in D, and all the
adherent and non-adherent cells were harvested and subject to FACS analysis as described in the second section. (F) Western blot analysis of PARP cleavage in total cell lysates of
MDA-MB-231 cells transiently transfected with GFP, GFP-BCL2L12 or GFP-BCL2L12A and treated with vehicle (PBS) or 10 μg/ml cisplatin for 24 h.
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effort to detect the mRNA levels of BCL2L12 and BCL2L12A in MCF-7
breast cancer cells upon cisplatin treatment. We found that the mRNA
levels of BCL2L12 and BCL2L12Awere ﬁrst upregulated before 8 h, and
then downregulated in the 16th hour in agreementwith Thomadaki et
al. where they found gene down regulation after 24 h treatment (Fig.
S1-B, C and D). These alterations of BCL2L12 level during drug
treatment implied a correlation between BCL2L12 and drug-induced
apoptosis.
However the downregulation or upregulation of BCL2L12 itself in
different cell lines and in response to different anti-tumor drugs could
not directly indicate an anti-apoptotic or pro-apoptotic function of
BCL2L12. For that both anti-apoptotic and pro-apoptotic proteins, such
as Bcl-2 and Bax, can be downregulated in drug-induced apoptosis
[41]. In order to clarify this, we explored an shRNA strategy to knock
down the endogenous BCL2L12 and it splicing variant BCL2L12A. With
an efﬁcient knockdown of BCL2L12 and BCL2L12A, MDA-MB-231 cells
showed an elevated resistance to cisplatin-induced apoptosis, as
analyzed by Annexin-V/PI double staining and PARP cleavage. And
ectopic expression of each of these proteins in MDA-NB-231 andMCF-
7 cells promoted cisplatin-induced apoptosis (Fig. 5 and Fig. S1). These
results implied that these two proteins might serve as pro-apoptoticproteins in cisplatin-induced apoptosis in MDA-NB-231 and MCF-7
cells.
As an anti-tumor drug, cisplatin was known to induce apoptosis of
tumor cells through DNA–DNA, DNA–protein crosslink and conse-
quent DNA damage. Adding the results proposed by Toumelin G.L. etc.
that BCL2L12 promoted UV-induced apoptosis [21], we hypothesize
that BCL2L12 and BCL2L12A might function as pro-apoptotic proteins
in DNA damage-induced apoptosis. However, the underlying mechan-
isms still need to be studied, and more efforts on other DNA damage
drugs and other cells should be made.
Although cisplatin-based chemotherapy is effective in treating
solid tumors, the acquisition of resistance by tumor cells to cisplatin is
one of the major problems in cisplatin treatment with largely
unknown mechanisms [44]. In our study, we found that knockdown
of endogenous BCL2L12 and BCL2L12A with a gene speciﬁc shRNA
dramatically inhibit cisplatin-induced apoptosis, while ectopic
expression of each of the proteins promoted cisplatin-induced
apoptosis. These ﬁndings indicated that decreased expressions or
loss of these two proteins may contribute to cisplatin resistance in
breast cancer patients. On the contrary, upregulated expressions of
both proteins might sensitize the tumor cells to cisplatin-based
chemotherapy. These results may also help to explain why these two
656 Y. Hong et al. / Biochimica et Biophysica Acta 1782 (2008) 649–657proteins were associated with favorable prognosis in breast cancer
patients.
β-catenin is a multifunctional protein involved in cell–cell
adhesion and Wnt signal transduction. β-catenin signaling has been
proposed to act as inducer of cell proliferation in different tumors [45].
In the nucleus, β-catenin acts as a transcriptional coactivator and
activates genes involved in cell proliferation and survival [46].
Misregulation of this important protein is a causative factor in some
human cancers. Downregulation of β-catenin is usually associated
with apoptosis [47]. We found in our study that β-catenin was
downregulated upon cisplatin treatment in MDA-MB-231 breast
cancer cells, which underwent apoptosis. However, this was partially
suppressed in BCL2L12- and BCL2L12A-knocked down MDA-MB-231
cells, which indicated that an elevated resistance of MDA-MB-231/pSi-
BCL2L12 in cisplatin-induced apoptosis may be associated with a
failure in β-catenin downregulation, and that BCL2L12 and BCL2L12A
may function through destabilization of β-catenin in cisplatin-
induced apoptosis.
We also found that the cell cycle distributions and growth rates
were similar in MDA-MB-231/pSilencer and MDA-MB-231/pSi-
BCL2L12 cells. This indicated that the favorable function of these
two proteins on breast cancer supposed by Maroulio Talieri etc. may
not be through cell cycle regulation but by inﬂuencing the tumor's
sensitivity to anti-tumor drugs [22].
In summary, the data presented here suggested that cisplatin
upregulated the expressions of BCL2L12 and BCL2L12A, which in turn
promoted cisplatin-induced apoptosis in MDA-MB-231 breast cancer
cells. Knockdown of BCL2L12 and BCL2L12A with a gene speciﬁc
shRNA dramatically inhibited cisplatin-induced apoptosis in MDA-
MB-231 cells. These ﬁndings suggested that BCL2L12 and BCL2L12A
play an important role in cisplatin-induced apoptosis. Conversely,
decreased expressions or loss of BCL2L12 and BCL2L12A might
contribute to the cisplatin resistance in breast cancer patients.
Acknowledgements
This workwas supported by Shanghai Leading Academic Discipline
Project (B110), Scientiﬁc Technology Development Foundation of
Shanghai (074307038), and the State Key Program of Basic Research of
China “973” (2002CB512803).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbadis.2008.09.008.
References
[1] R.D. Snyder, New concepts in breast cancer therapy, Intern. Med. J. 34 (2004)
266–269.
[2] Ahmedin Jemal, DVM, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu,
Taylor Murray, and Michael J.Thun, Cancer Statistics, 2008. CA Cancer J Clin 58
(2008) 71–96.
[3] M. Martin, Platinum compounds in the treatment of advanced breast cancer, Clin.
Breast Cancer 2 (2001) 190–208.
[4] J.P. Crown, The platinum agents: a role in breast cancer treatment? Semin. Oncol.
28 (2001) 28–37.
[5] G.N. Hortobagyi, Chemotherapy of breast cancer: a historical perspective, Semin.
Oncol. 24 (1997) S17.
[6] Z.H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance,
Oncogene 22 (2003) 7265–7279.
[7] E.M. Yazlovitskaya, D.L. Persons, Inhibition of cisplatin-induced ATR activity and
enhanced sensitivity to cisplatin, Anticancer Res. 23 (2003) 2275–2279.
[8] Q.Wei, G. Dong, T. Yang, J. Megyesi, P.M. Price, Z. Dong, Activation and involvement
of p53 in cisplatin-induced nephrotoxicity, Am. J. Physiol. Renal Physiol. 293
(2007) F1282–F1291.
[9] K. Yoshida, T. Ozaki, K. Furuya, M. Nakanishi, H. Kikuchi, H. Yamamoto, S. Ono, T.
Koda, K. Omura, A. Nakagawara, ATM-dependent nuclear accumulation of IKK-
alpha plays an important role in the regulation of p73-mediated apoptosis in
response to cisplatin, Oncogene 27 (2008) 1183–1188.[10] P. Bragado, A. Armesilla, A. Silva, A. Porras, Apoptosis by cisplatin requires p53
mediated p38alpha MAPK activation through ROS generation, Apoptosis 12
(2007) 1733–1742.
[11] H. Niedner, R. Christen, X. Lin, A. Kondo, S.B. Howell, Identiﬁcation of genes that
mediate sensitivity to cisplatin, Mol. Pharmacol. 60 (2001) 1153–1160.
[12] T. Funato, K. Kozawa, M. Kaku, T. Sasaki, Modiﬁcation of the sensitivity to cisplatin
with c-myc over-expression or down-regulation in colon cancer cells, Anticancer
Drugs 12 (2001) 829–834.
[13] M. Fraser, T. Bai, B.K. Tsang, Akt promotes cisplatin resistance in human ovarian
cancer cells through inhibition of p53 phosphorylation and nuclear function, Int. J.
Cancer 122 (2008) 534–546.
[14] H. Niedner, R. Christen, X. Lin, A. Kondo, S.B. Howell, Identiﬁcation of genes that
mediate sensitivity to cisplatin, Mol. Pharmacol. 60 (2001) 1153–1160.
[15] R.J. Youle, A. Strasser, The BCL-2 protein family: opposing activities that mediate
cell death, Nat. Rev. Mol. Cell Biol. 9 (2008) 47–59.
[16] J.E. Chipuk, D.R. Green, How do BCL-2 proteins induce mitochondrial outer
membrane permeabilization? Trends Cell Biol. 18 (2008) 157–164.
[17] C. Borner, The Bcl-2 protein family: sensors and checkpoints for life-or-death
decisions, Mol.Immunol. 39 (2003) 615–647.
[18] R. Simstein, M. Burow, A. Parker, C. Weldon, B. Beckman, Apoptosis, chemoresis-
tance, and breast cancer: insights from the MCF-7 cell model system, Exp. Biol.
Med. (Maywood.) 228 (2003) 995–1003.
[19] P. Costantini, E. Jacotot, D. Decaudin, G. Kroemer, Mitochondrion as a novel target
of anticancer chemotherapy, J. Natl. Cancer Inst. 92 (2000) 1042–1053.
[20] A. Scorilas, L. Kyriakopoulou, G.M. Yousef, L.K. Ashworth, A. Kwamie, E.P.
Diamandis, Molecular cloning, physical mapping, and expression analysis of a
novel gene, BCL2L12, encoding a proline-rich proteinwith a highly conserved BH2
domain of the Bcl-2 family, Genomics 72 (2001) 217–221.
[21] G.L. Toumelin, A. Mazars, A. Licznar, G. Guasconi, J.C. Rain, N. Cauquil, John
Hickman, Olivier Geneste, Bcl2L12, a new BH2 BH3 containing protein, substrate
for GSK3beta, mediates UV induced apoptosis, Proc. Amer. Assoc. Cancer Res 47
(2006).
[22] M. Talieri, E.P. Diamandis, N. Katsaros, D. Gourgiotis, A. Scorilas, Expression of
BCL2L12, a new member of apoptosis-related genes, in breast tumors, Thromb.
Haemost. 89 (2003) 1081–1088.
[23] M. Sun, Y. Wei, L. Yao, J. Xie, X. Chen, H. Wang, J. Jiang, J. Gu, Identiﬁcation of
extracellular signal-regulated kinase 3 as a new interaction partner of cyclin D3,
Biochem. Biophys. Res. Commun. 340 (2006) 209–214.
[24] H. Wang, H. Shen, Y. Wang, Z. Li, H. Yin, H. Zong, J. Jiang, J. Gu, Overexpression of
small glutamine-rich TPR-containing protein promotes apoptosis in 7721 cells,
FEBS Lett. 579 (2005) 1279–1284.
[25] Z. Herceg, Z.Q.Wang, Failure of poly(ADP-ribose) polymerase cleavage by caspases
leads to induction of necrosis and enhanced apoptosis, Mol. Cell Biol. 19 (1999)
5124–5133.
[26] H. Thomadaki, M. Talieri, A. Scorilas, Prognostic value of the apoptosis related
genes BCL2 and BCL2L12 in breast cancer, Cancer Lett. 247 (2007) 48–55.
[27] J.C. Reed, Bcl-2 family proteins, Oncogene 17 (1998) 3225–3236.
[28] J.C. Reed, K.S. Doctor, A. Godzik, The domains of apoptosis: a genomics
perspective, Sci.STKE. 2004 (2004) re9.
[29] J.C. Reed, Bcl-2-family proteins and hematologic malignancies: history and future
prospects, Blood 111 (2008) 3322–3330.
[30] S. Willis, C.L. Day, M.G. Hinds, D.C. Huang, The Bcl-2-regulated apoptotic pathway,
J. Cell Sci. 116 (2003) 4053–4056.
[31] A.H. Stegh, H. Kim, R.M. Bachoo, K.L. Forloney, J. Zhang, H. Schulze, K. Park, G.J.
Hannon, J. Yuan, D.N. Louis, R.A. DePinho, L. Chin, Bcl2L12 inhibits post-
mitochondrial apoptosis signaling in glioblastoma, Genes Dev. 21 (2007) 98–111.
[32] A.R. Stankiewicz, G. Lachapelle, C.P. Foo, S.M. Radicioni, D.D. Mosser, Hsp70
inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax
translocation, J. Biol. Chem. 280 (2005) 38729–38739.
[33] T. Gotoh, K. Terada, S. Oyadomari, M. Mori, hsp70-DnaJ chaperone pair prevents
nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to
mitochondria, Cell Death Differ. 11 (2004) 390–402.
[34] R. Ran, A. Lu, L. Zhang, Y. Tang, H. Zhu, H. Xu, Y. Feng, C. Han, G. Zhou, A.C. Rigby, F.
R. Sharp, Hsp70 promotes TNF-mediated apoptosis by binding IKK gamma and
impairing NF-kappa B survival signaling, Genes Dev. 18 (2004) 1466–1481.
[35] N.S. Wang, M.T. Unkila, E.Z. Reineks, C.W. Distelhorst, Transient expression of
wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient
expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-
induced cell death, J. Biol. Chem. 276 (2001) 44117–44128.
[36] E.J. Uhlmann, T. Subramanian, C.A. Vater, R. Lutz, G. Chinnadurai, A potent cell
death activity associated with transient high level expression of BCL-2, J. Biol.
Chem. 273 (1998) 17926–17932.
[37] K. Mathioudaki, A. Scorilas, A. Papadokostopoulou, D. Xynopoulos, N. Arnogianaki,
N. Agnanti, M. Talieri, Expression analysis of BCL2L12, a newmember of apoptosis-
related genes, in colon cancer, Biol. Chem. 385 (2004) 779–783.
[38] H. Thomadaki, A. Scorilas, Breast cancer cells response to the antineoplastic agents
cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct
apoptosis-related genes, including the newmember, BCL2L12, Ann. N.Y. Acad. Sci.
1095 (2007) 35–44.
[39] K.V. Floros, H. Thomadaki, D. Florou, M. Talieri, A. Scorilas, Alterations in mRNA
expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel
member BCL2L12 after treatment of human leukemic cell line HL60 with the
antineoplastic agent etoposide, Ann. N.Y. Acad. Sci. 1090 (2006) 89–97.
[40] K.V. Floros, M. Talieri, A. Scorilas, Topotecan and methotrexate alter expression of
the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells, Biol.
Chem. 387 (2006) 1629–1633.
657Y. Hong et al. / Biochimica et Biophysica Acta 1782 (2008) 649–657[41] H. Thomadaki, M. Talieri, A. Scorilas, Treatment of MCF-7 cells with taxol and
etoposide induces distinct alterations in the expression of apoptosis-related genes
BCL2, BCL2L12, BAX, CASPASE-9 and FAS, Biol. Chem. 387 (2006) 1081–1086.
[42] K.V. Floros, H. Thomadaki, N. Katsaros, M. Talieri, A. Scorilas, mRNA expression
analysis of a variety of apoptosis-related genes, including the novel gene of the
BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin
and doxorubicin, Biol. Chem. 385 (2004) 1099–1103.
[43] K.V. Floros, H. Thomadaki, G. Lallas, N. Katsaros, M. Talieri, A. Scorilas, Cisplatin-
induced apoptosis in HL-60 human promyelocytic leukemia cells: differentialexpression of BCL2 and novel apoptosis-related gene BCL2L12, Ann. N.Y. Acad. Sci.
1010 (2003) 153–158.
[44] G. Chu, Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA
repair, J.Biol.Chem. 269 (1994) 787–790.
[45] M. Peifer, -βcatenin as oncogene: the smoking gun, Science 275 (1997) 1752–1753.
[46] B. Bowerman, Oxidative stress and cancer: β-catenin convergence, Science 308
(2005) 1119–1120.
[47] Y.Z. Chen, APP induces neuronal apoptosis through APP-BP1-mediated down-
regulation of β-catenin, Apoptosis 9 (2004) 415–422.
